2026 IMS｜驯鹿生物福可苏® FUMANBA-1研究更新揭示CAR-T细胞体内持久存续与长期MRD阴性及延缓疾病进展相关
中国南京、上海和美国普莱森顿 2026年9月25日 /美通社/ -- 驯鹿生物，一家致力于发现、开发、生产和商业化血液恶性肿瘤及自身免疫性疾病创新细胞疗法与生物制剂的生物制药公司，今日宣布其全球首款全人源靶向BCMA CAR-T细胞治疗产品——福可苏®（伊基奥仑赛注射液，Eque-cel）的关键注册研究临床FUMANBA-1的一项回顾性分析结果，在2026年国际骨髓瘤学会（IMS）年会上以壁报形式展示 [1] （摘要号：PA-469）。结果显示，福可苏® CAR-T细胞在患者体内的持久存续（以外周血载体拷贝数[VCN]评估）与持续微小残留病（MRD）阴性和至疾病进展时间（TTP）延长相关；且伴有del(17p)、高肿瘤负荷及疾病快速…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →